Sehgal, Alfica
Alnylam Pharmaceuticals (United States)
5 papers on CoChat
Most cited papers
- Verified
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine
Amyloidosis: Diagnosis, Treatment, OutcomesRNA Interference and Gene Delivery
Cited by 971
- Verified
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
Foster, D. J., Brown, C. R., Shaikh, S., Trapp, C., Schlegel, M. K., Qian, K., Sehgal, A., Rajeev, K. G., Jadhav, V., Manoharan, M., et al. (2018) · Molecular Therapy
RNA Interference and Gene DeliveryDNA and Nucleic Acid Chemistry
Cited by 325
- Verified
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
Nair, J. K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S., et al. (2017) · Nucleic Acids Research
RNA Interference and Gene DeliveryDNA and Nucleic Acid Chemistry
Cited by 278
- Verified
The Polyploid State Plays a Tumor-Suppressive Role in the Liver
Zhang, S., Zhou, K., Luo, X., Li, L., Tu, H.-C., Sehgal, A., Nguyen, L. H., Zhang, Y., Gopal, P., Tarlow, B. D., et al. (2018) · Developmental Cell
Liver physiology and pathologyCancer-related Molecular Pathways
Cited by 180
- Verified
Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification
Chan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K., et al. (2015) · Molecular Therapy — Nucleic Acids
Porphyrin Metabolism and DisordersRNA Interference and Gene Delivery
Cited by 128
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free